Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of Vibroakustik

February 13, 2024 M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Vibroakustik Sverige AB (”Vibroakustik”).

Vibroakustik is a consulting company specialised in reducing environmental impact and improving the working environment through advanced measurement and analysis services. Within environmental impact, Vibroakustik takes a holistic approach to environmental challenges, with an emphasis on risk analysis, inspections and measurement and analysis of noise and vibration in order to ensure that major construction and infrastructure projects comply with environmental requirements and that the adverse impact on the environment is minimised.

Vinge’s team consisted of responsible partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Gustav Persson, Sara Passandideh and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026